Discovery of antibody structure could lead to treatment for Crimean Congo Hemorrhagic Fever virus


A research team led by the University of California, Riverside, has discovered important details about how therapeutically relevant human monoclonal antibodies can protect against Crimean Congo Hemorrhagic Fever virus, or CCHFV. Their work, which appears in the journal Nature Communications, could lead to the development of targeted therapeutics for infected patients.

Twitter’s character limit might jump from 280 to 1,000

Previous article

Simultaneous radiation and immunotherapy found to be beneficial for a subset of lung cancer patients

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations